Anteris Technologies (AVR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Nov, 2026Executive summary
Annual meeting scheduled for Dec. 2, 2026, in Sydney and by webcast; record date Oct. 29, 2026. Stockholders will consider 23 proposals.
Board recommends FOR all proposals, spanning director elections, KPMG ratification, equity awards, amendments to existing RSUs, and director retainer payments in equity.
Voting matters and shareholder proposals
Elect David St Denis and Stephen Denaro as Class II directors for terms through the 2029 annual meeting; both are non-independent under Nasdaq criteria.
Ratify KPMG for FY2026; Proposal Two is the sole routine matter eligible for broker discretionary voting.
Proposals 3–15 and 17–18 seek ASX approval for executive and director RSUs, options, and PSUs; Proposal 16 seeks cash settlement elections for certain outstanding RSUs.
Proposals 19–23 authorize up to $540,000 for John Seaberg and $330,000 each for four other directors in shares or CDIs instead of cash retainers, if directors elect equity.
Most proposals require an affirmative majority of shares present and entitled to vote; director elections use plurality. Abstentions count against other proposals.
Board of directors and corporate governance
Seven-member classified Board; four directors qualify as independent under Nasdaq rules. Chair John Seaberg and CEO Wayne Paterson hold separate roles.
Audit and Risk, Compensation, and Nominating and Corporate Governance committees each have four independent members; Susan Knight chairs Audit and Risk, Gregory Moss Compensation, and David Roberts Nominating and Corporate Governance.
Directors are nominated against criteria including integrity, leadership, financial expertise, industry background, time commitment, and diversity of viewpoints and experience.
In FY2025, the Board held eight meetings, Audit and Risk four, Compensation five, and Nominating and Corporate Governance none; directors serving during the period attended all relevant meetings.
Latest events from Anteris Technologies
- PARADIGM expands as funding supports trial execution and manufacturing scale-up.AVR
Q3 2026 - 23 proposals seek director elections, auditor ratification and extensive equity awards.AVR
Proxy filing - Q2 2026 featured global trial expansion, U.S. Medicare reimbursement, and strong cash growth.AVR
Q2 2026 TU - Shareholders considered and voted on a US redomicile scheme, with board and expert support.AVR
Share Scheme Meeting - Pre-commercial heart device company targets U.S. IPO to fund pivotal trials amid high growth potential and risk.AVR
Registration filing - Raising $90.6M to fund heart valve trials, but faces ongoing losses and high risk.AVR
Registration filing - US IPO, clinical milestones, and strong R&D focus marked a pivotal year.AVR
AGM 2025 - Operating losses widened as PARADIGM Trial preparations accelerated and cash fell to $28.4M.AVR
Q2 2025 TU - Option holders voted on a scheme to exchange their options for equivalent securities in ATGC.AVR
Option Scheme Meeting